Abstract: The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.
Abstract: The present disclosure relates to the preparation of methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate (ITE) and related compounds with high yield, purity, and scalability. The processes apply the use of a Weinreb amide intermediate as a scaffold for the preparation of ITE and structural analogs.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
October 5, 2021
Assignee:
Noramco, LLC
Inventors:
Martin Benedict Strack, Jasper Kaiser, Gnel Mkrtchyan, Wen-Chun Zhang
Abstract: Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
Abstract: A compound of formula (I), or an N-oxide thereof is provided. In the compound of formula (I), Het1 represents Het1-1, Het1-2, Het1-3, Het1-4, Het1-5, Het1-6, Het1-7, Het1-8, or Het1-9, and the remaining variable groups are as defined in the specification. The compound of formula (I), or N-oxide thereof has a superior effect in controlling arthropod pests.
Abstract: Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions. Also provided herein are methods of preventing or delaying the onset of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject. Also provided herein are methods of reducing or preventing the progression of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
September 14, 2021
Assignee:
Aerie Pharmaceuticals, Inc.
Inventors:
Eric Carlson, Mitchell A. deLong, Heeren Gordhan, Cynthia L. Lichorowic, Jill M. Sturdivant
Abstract: The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.
Type:
Grant
Filed:
June 26, 2020
Date of Patent:
September 7, 2021
Assignee:
ADLAI NORTYE BIOPHARMA CO., LTD.
Inventors:
Pan Li, Qiaodong Wen, Ji Wang, Quan Gan, Yang Lu, Donghui Yang
Abstract: The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Type:
Grant
Filed:
June 7, 2018
Date of Patent:
September 7, 2021
Assignee:
Global Blood Therapeutics, Inc.
Inventors:
Chul Yu, Ming Yu, Manuel Zancanella, Zhe Li
Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
Type:
Grant
Filed:
October 16, 2020
Date of Patent:
August 31, 2021
Assignee:
Morphic Therapeutic, Inc.
Inventors:
Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
Abstract: The present invention relates to a method of preparing racemic nicotine comprising: (i) reacting ethyl nicotinate and N-vinylpyrrolidone in the presence of an alcoholate base to 3-nicotinoyl-1-vinylpyrrolidin-2-one; (ii) reacting the 3-nicotinoyl-1-vinylpyrrolidin-2-one with an acid to myosmine; (iii) reducing the myosmine to nornicotine using a reducing agent; and (iv) methylating the nornicotine to obtain the racemic nicotine.
Abstract: The subject-matter of the invention is process for the separation of optical isomers of racemic 3-alk-3-carboxylic acid ethyl esters of formula rac-I with the resolving agent (II) (?)-2,3:4,5-di-O-izopropylidene-2-keto-L-gulonic acid (hereinafter: diacetone-L-ketogulonic acid).
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
August 17, 2021
Assignee:
RICHTER GEDEON NYRT.
Inventors:
Ferenc Faigl, Béla Mátravölgyi, Ágnes Mizsák
Abstract: The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.
Abstract: The anionic imide material is obtained by preparing a solution or a suspension of an imide compound, then reducing and drying the same; the anionic material comprises anions of an imide compound, the anions being at least one selected from the following formula I or formula II; in formula I or II: n=1, 2, or 3; R1, R2 are respectively selected from at least one of H, amino, carboxyl, hydroxy, thiol, and pyridyl groups; X1-X4 are respectively an electron withdrawing group, and specifically selected from one of H, F, Cl, Br, CN, and NO2 groups. The anionic material of the present invention has a Curie temperature larger than room temperature and ferromagnetism, and is an organic magnetic material; it may be used for preparing an organic magnetic material and/or an organic magnetic device.
Type:
Grant
Filed:
July 25, 2018
Date of Patent:
August 10, 2021
Assignee:
SOUTH CHINA UNIVERSITY OF TECHNOLOGY
Inventors:
Dehua Hu, Qinglin Jiang, Yuguang Ma, Duokai Zhao, Jiang Zhang, Zhongquan Mao, Yao Yao
Abstract: A method for preparing 1,2,4-triazole includes using a fluoroborate aryl diazonium salt, a diazoester derivative and an organic nitrile as reaction substrates, a transition metal salt as a catalyst, and an inorganic base as an additive in a cyclization reaction. The method has the following characteristics: the reaction is economical; the substrate is universal; the post-functionalization is easy; the reaction conditions are mild; the reaction can be performed in air; the catalyst amount used is less; and the post-treatment is simple. Meanwhile, the raw materials, such as the reactants and the catalyst used, are inexpensive and easily available; the reaction composition is reasonable; no ligand is needed; there are less reaction steps; and only one step of reaction is required to obtain a high yield, meeting the requirements and directions of contemporary green chemistry and medicinal chemistry, being suitable for screening highly active 1,2,4-triazole drugs.
Type:
Grant
Filed:
October 11, 2020
Date of Patent:
July 27, 2021
Inventors:
Haiyan Li, Huihuang Li, Yaxiong Wang, Xiaobing Wan
Abstract: The present invention provides a compound having the structure: for use in combination with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
July 27, 2021
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Abstract: Various fentanyl derivatives are described. The derivatives exhibit high binding affinity to opioid receptors, but also have decreased blood brain permeability as compared to standard fentanyl. This, the resulting derivatives can be less addictive than standard fentanyl. Methods of making such derivatives are also disclosed in this document.
Type:
Grant
Filed:
September 6, 2016
Date of Patent:
July 20, 2021
Assignee:
Allegheny-Singer Research Institute
Inventors:
Saadyah Averick, Ahmed Badr, Shaohua Li, Keith LeJeune
Abstract: The present invention relates to compounds I wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and intermediates for compounds I.
Type:
Grant
Filed:
July 18, 2016
Date of Patent:
July 20, 2021
Assignee:
BASF SE
Inventors:
Wassilios Grammenos, Christian Winter, Bernd Mueller, Antje Wolf, Ana Escribano Cuesta, Erica Cambeis, Jan Klaas Lohmann, Thomas Grote, Manuel Kretschmer, Nadine Riediger, Ian Robert Craig, Christine Wiebe, Violeta Terterya-Seiser, Andreas Koch, Marcus Fehr
Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
Type:
Grant
Filed:
December 6, 2019
Date of Patent:
July 13, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
Abstract: A pharmaceutically acceptable salt as a renal outer medullary potassium channel (ROMK) inhibitor, specifically an L-tartrate and a crystal form I and crystal form II thereof, is described. The pharmaceutically acceptable salt of the ROMK inhibitor, specifically the L-tartrate, has improved bioavailability and stability.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
July 13, 2021
Assignee:
Jiangsu Hengrui Medicine Co., Ltd.
Inventors:
Yun Lu, Qiyun Shao, Guaili Wu, Jun Feng
Abstract: The application includes a description of novel intermediates, of new manufacturing steps resulting in a novel and improved process for producing the intermediates and the final compounds, i.e., 6-alkynyl-pyridine derivatives. The intermediates of the invention are useful to produce 6-alkynyl-pyridine derivatives, which compounds are useful for the treatment of cancer.
Type:
Grant
Filed:
May 17, 2017
Date of Patent:
July 6, 2021
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Guanghua Lu, Guenther Huchler, Thomas Krueger, Michael Pangerl, Marco Santagostino, Jean-Nicolas Desrosiers